Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Conference News AHA 2024

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Michael O'Riordan

November 17, 2024

News Daily News

New Guidelines for CV Care in Patients Undergoing Noncardiac Surgery

Michael O'Riordan

September 24, 2024

News Daily News

Statins Are Cost-effective in the Elderly

Michael O'Riordan

September 11, 2024

News Conference News ESC 2024

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

Todd Neale

September 06, 2024

News Conference News ESC 2024

STEEER-AF: Educating Healthcare Workers Improves Adherence to Guidelines

Todd Neale

September 06, 2024

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

Presentation ESC 2024

Stroke prevention & rhythm control Therapy: Evaluation of an Educational programme of the European society of cardiology in a cluster-Randomised trial in patients with Atrial Fibrillation

Presenter: Dipak Kotecha

September 01, 2024

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

News Daily News

PREVENT Risk Calculator Means Fewer Patients on Statins, Antihypertensives

Michael O'Riordan

August 02, 2024

News Daily News

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

Michael O'Riordan

July 09, 2024

News Daily News

Think You Need a Statin? AHA’s Risk Calculator May Disagree

Michael O'Riordan

June 28, 2024

News Conference News NY Valves 2024

National Data Point to Soaring TAVI Rates in Patients Under 65

Michael O'Riordan

June 14, 2024

News Conference News NY Valves 2024

Good 3-Year Outcomes With Aortic Valve-in-Valve Replacement for Failed SAVR

Michael O'Riordan

June 11, 2024

News Daily News

Excess ApoB Linked to Increased MI, ASCVD Risk in Adults

Michael O'Riordan

June 04, 2024

News

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Michael O'Riordan

May 30, 2024

News Daily News

Statins Effective For Primary Prevention in Old and Very Old

Michael O'Riordan

May 29, 2024

News Daily News

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

Yael L. Maxwell

May 08, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

Advertisement

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

New Guidelines for CV Care in Patients Undergoing Noncardiac Surgery

Statins Are Cost-effective in the Elderly

Streamlined European AF Guidelines Emphasize ‘Whole’ Patient

STEEER-AF: Educating Healthcare Workers Improves Adherence to Guidelines

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Stroke prevention & rhythm control Therapy: Evaluation of an Educational programme of the European society of cardiology in a cluster-Randomised trial in patients with Atrial Fibrillation

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

PREVENT Risk Calculator Means Fewer Patients on Statins, Antihypertensives

Apixaban May Have Advantages in Patients With Liver Cirrhosis and AF

Think You Need a Statin? AHA’s Risk Calculator May Disagree

National Data Point to Soaring TAVI Rates in Patients Under 65

Good 3-Year Outcomes With Aortic Valve-in-Valve Replacement for Failed SAVR

Excess ApoB Linked to Increased MI, ASCVD Risk in Adults

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Statins Effective For Primary Prevention in Old and Very Old

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content